Effects of 18beta-solidum glycrrhetinic acid on nuclear factor-kappaBp50 of nasal mucosa and IL-4 of serum in rats with allergic rhinitis
- Author:
Li LI
1
Author Information
- Publication Type:Journal Article
- Keywords: 18beta-solidum glycrrhetinic acid; Allergic rhinitis; Interleukin-4; Nuclear factor-kappaBp50
- From: Journal of Xi'an Jiaotong University(Medical Sciences) 2020;41(1):58-63
- CountryChina
- Language:Chinese
- Abstract: Objective: To investigate the effects of 18beta-solidum glycrrhetinic acid (18β-SGA) on the expression of nuclear factor-kappaBp50 (NF-κBp50) in nasal mucosa and interleukin-4 (IL-4) in serum of allergic rhinitis (AR) rats. Methods:Wistar rats were sensitized with ovalbumin (OVA) to establish an animal model of AR. After successful modeling, the rats were randomly divided into control group, model group, budesonide group and 18β-SGA different dose treatment groups (20 mg/kg group and 40 mg/kg group). The nasal mucosa and serum was collected at 2 weeks and 4 weeks after administration. The distribution of NF-κBp50 in nasal mucosa was observed by immunohistochemistry. RT-qPCR and Western blot were used to detect NF-κBp50 expression. ELISA was used to detect OVA-specific immunoglobulin E (OVA-sIgE) and IL-4 expression in serum. Results: The results of immunohistochemistry showed that NF-κBp50 was mainly expressed in nasal mucosa's cytoplasm and nucleus of pseudostratified ciliated columnar epithelium, vascular endothelial cells in the lamina propria, glandular cells and inflammatory cells. RT-qPCR and Western blot analysis showed that the relative expressions of NF-κBp50 mRNA and protein in nasal mucosa of AR rats were increased compared with those in normal rats (P<0.05), but they were decreased after treatment with 18β-SGA or budesonide (P<0.05). ELISA showed that the expressions of OVA-sIgE and IL-4 in serum of AR rats were increased compared with those in normal rats (P<0.05), but the expression of IL-4 in AR rats decreased after treatment with 18β-SGA or budesonide (P<0.05). Conclusion: 18β-SGA can significantly inhibit the activity of NF-κB, and decrease the expressions of NF-κBp50 and IL-4. Therefore, it has anit-inflammatory action and may be used in the treatment of AR.
